Rosenthal T, Ezra D
A.J. Chorley Institute for Hypertension, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Drug Saf. 1995 Sep;13(3):157-87. doi: 10.2165/00002018-199513030-00003.
The interaction of calcium antagonists, including the dihydropyridine calcium antagonists (e.g. nifedipine), verapamil and diltiazem, with drugs from other classes has major clinical ramifications as the use of drug combinations increases in frequency. Combinations are used in the treatment of disorders ranging from hypertension to cardiac rhythm disturbances, angina pectoris and peripheral vasospastic disease. In this era of organ transplantation, drugs like cyclosporin are coming into potential conflict with an ever-growing list of drugs. Drug combinations used as part of long term therapies are also making their appearance in toxic drug reactions, including antituberculous and anticonvulsant agents. Bronchodilators and H2-blockers also fall into this category of potential culprits of combined drug toxicity, and the interactions of calcium antagonists with beta-blockers and antiarrhythmic agents are also becoming a matter of concern.
随着联合用药的频率不断增加,包括二氢吡啶类钙拮抗剂(如硝苯地平)、维拉帕米和地尔硫䓬在内的钙拮抗剂与其他类药物之间的相互作用具有重大的临床意义。联合用药被用于治疗从高血压到心律失常、心绞痛和外周血管痉挛性疾病等各种病症。在器官移植的这个时代,环孢素等药物与越来越多的药物存在潜在冲突。作为长期治疗一部分使用的联合用药也出现在药物毒性反应中,包括抗结核药和抗惊厥药。支气管扩张剂和H2受体阻滞剂也属于联合药物毒性的潜在罪魁祸首这一类别,钙拮抗剂与β受体阻滞剂和抗心律失常药物之间的相互作用也日益受到关注。